The Jamaican Court of Appeal on Friday handed down its judgement on the Lasco Distributors and Medimpex appeal of the judgement received by the lower court against Pfizer. The court dismissed the appeals and awarded cost to Pfizer.
Lasco
According to the Court of Appeal, the learned judge awarded Lasco approximately $273.3 million and Medimpex, approximately $170,8 million in damages. Those figures included interest on the various sums that comprised the award. Lasco and Medimpex were both dissatisfied with their respective awards and, in separate appeals, sought to have this court increase them.
Pfizer resisted both appeals, which were consolidated and heard together. Although the appellants have filed numerous grounds of appeal, the essence of their respective complaints is that the learned judge erred in calculating the size of the amlodipine market, the potential growth of that market, miscalculating the market share for the respective versions of amlodipine sold by each of the appellants, adopting an inappropriate market scenario and applying an inappropriate discount to the market scenario that she adopted. 
She also had a misunderstanding of the post-injunction sales scenarios for the respective versions of amlodipine sold by the appellants and applied an inappropriate rate of interest to the respective awards of damages.
Lasco Distributors is listed on the Jamaica Stock Exchange Junior Market.
The latest award would be highly disappointing for Lasco who had claimed some US$300 million initially and would have collected a fraction of that amount.
